 Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 4 | 2 | 6 | | 1993 | 3 | 0 | 3 | | 1994 | 9 | 1 | 10 | | 1995 | 3 | 1 | 4 | | 1996 | 7 | 2 | 9 | | 1997 | 8 | 5 | 13 | | 1998 | 7 | 3 | 10 | | 1999 | 4 | 1 | 5 | | 2000 | 8 | 1 | 9 | | 2001 | 7 | 2 | 9 | | 2002 | 16 | 3 | 19 | | 2003 | 11 | 0 | 11 | | 2004 | 15 | 2 | 17 | | 2005 | 18 | 3 | 21 | | 2006 | 19 | 3 | 22 | | 2007 | 16 | 1 | 17 | | 2008 | 15 | 3 | 18 | | 2009 | 14 | 1 | 15 | | 2010 | 22 | 1 | 23 | | 2011 | 14 | 2 | 16 | | 2012 | 36 | 2 | 38 | | 2013 | 31 | 8 | 39 | | 2014 | 30 | 1 | 31 | | 2015 | 31 | 0 | 31 | | 2016 | 32 | 1 | 33 | | 2017 | 40 | 1 | 41 | | 2018 | 39 | 2 | 41 | | 2019 | 35 | 1 | 36 | | 2020 | 23 | 2 | 25 | | 2021 | 30 | 0 | 30 | | 2022 | 27 | 0 | 27 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 Sep 06; 21(9):1381-1392.
-
Vu NT, Kim M, Stephenson DJ, MacKnight HP, Chalfant CE. Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function. Mol Cancer Res. 2022 Sep 02; 20(9):1429-1442.
-
Jahanzeb M, Lin HM, Wu Y, Zhang P, Gorritz M, McGuiness CB, Huang WT, Sun K, Chen CC, Camidge DR. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. Oncologist. 2022 Sep 02; 27(9):790-798.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin. 2022 Sep; 38(9):1587-1593.
-
Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discov. 2022 Jul 06; 12(7):1676-1689.
-
Vu T, Wrobel J, Bitler BG, Schenk EL, Jordan KR, Ghosh D. SPF: A spatial and functional data analytic approach to cell imaging data. PLoS Comput Biol. 2022 06; 18(6):e1009486.
-
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 07 14; 387(2):120-131.
-
Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions? Clin Cancer Res. 2022 06 01; 28(11):2204-2205.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol. 2022 Jun; 18(20):2499-2510.
-
Davies KD, Ritterhouse LL, Snow AN, Sidiropoulos N. MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer. J Mol Diagn. 2022 08; 24(8):841-843.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|